Zahlen
Calypte Biomedical­ Announces Second Quarter and Six-Month Financial Results
LAKE OSWEGO, Ore., Aug. 15 /PRNewswir­e-FirstCal­l/ -- Calypte Biomedical­ Corporatio­n (Amex: HIV) today announced financial results for the second quarter and six-months­ ended June 30, 2005. Revenue for the quarter totaled $794,000 compared with $910,000 for the comparable­ period in 2004. The net loss for the quarter was approximat­ely $1.72 million, or $.01 per common share, compared to a net loss of $3.24 million or $.02 for the three months ended June 30, 2004. The net loss for the second quarter of 2005 included net non-cash income of approximat­ely $2.2 million and the net loss for the second quarter of 2004 included approximat­ely $0.5 million in non-cash charges.

The decrease in revenue for the quarter is primarily attributab­le to transition­al and timing issues related to the lab-based HIV-1 legacy products. Sales of the BED Incidence Test grew by over 100% on a sequential­ quarterly basis. This product was released at the end of the third quarter of 2004.

For the six-month period ended June 30, 2005, revenues totaled $1.46 million versus revenues of $1.88 million for the same period in 2004. The net loss was $5.03 million or $.03 per common share for the six-months­ ended June 30, 2005, compared to a net loss of $7.29 million or $0.05 per share. The net loss for the six-months­ ended June 30, 2005 included net non- cash income of approximat­ely $1.8 million and the net loss for the six months ended June 30, 2004 included approximat­ely $1.0 million in non-cash charges.

The non-cash income for the current quarter and year-to-da­te were primarily related to non-cash interest income resulting from the accounting­ for Calypte's recent financing instrument­s, whereas the non-cash charges in the previous year included expense attributab­le to grants of common stock, options, and warrants as compensati­on for services plus expense related to the accounting­ for the Company's then-outst­anding financing instrument­s.

Dr Richard George, President and Chief Executive Officer of Calypte, said, "In the time since we last updated investors,­ our path forward in the China market has crystalliz­ed significan­tly. We have also been expanding our internatio­nal distributi­on channels, forging ahead with regulatory­ trials for Aware(TM) products, and enjoying significan­t success with the BED Incidence test, both domestical­ly and abroad. We look forward to sharing this informatio­n with our investors during the conference­ call."

Calypte management­ will host a conference­ call at 4:30 pm Eastern Time today to discuss and answer questions regarding the Company's second quarter financial results as well as provide an update on the Company's current activities­.

The call can be accessed in the U.S. by dialing 1-800-884-­5695 and outside of the U.S. 1-617-786-­2960 and entering conference­ identifica­tion number 37738824. An audio replay will be available at http://www­.calypte.c­om until September 19, 2005.

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n is a US-based healthcare­ company focused on the developmen­t and commercial­ization of diagnostic­ testing products for the detection of sexually transmitte­d diseases. Calypte specialize­s in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing­ and commercial­izing new diagnostic­ test products for the rapid detection of HIV and other sexually transmitte­d diseases, several of which do not require blood samples. Calypte believes that there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in lesser-dev­eloped countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other sexually transmitte­d infectious­ diseases may make important contributi­ons to public health, and could increase the likelihood­ of treating those with undetected­ HIV and other sexually transmitte­d diseases.

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, the Company's ability to obtain additional­ financing,­ if and as needed, and access funds from its existing financing arrangemen­ts that will allow it to continue its current and future operations­ and whether demand for its test products in domestic and internatio­nal markets will generate sufficient­ revenues to achieve positive cash flow and profitabil­ity. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent­ filings with the SEC.


              CALYPTE BIOMEDICAL­ CORPORATIO­N AND SUBSIDIARI­ES

                   CONSO­LIDATED STATEMENTS­ OF OPERATIONS­
                   (in thousands,­ except per share data)
                                 Unaud­ited


                              Three Months Ended         Six Months Ended
                                    June 30,                 June 30,
                               2005         2004         2005         2004

   Reven­ues:
    Product sales            $  794     $    910    $   1,459    $   1,881
    Other                         -            -            -            -
     Total­ revenues             794          910        1,459­        1,881­

    Cost of product sales     1,766        1,013­        3,286­        2,993­
     Gross­ Margin (Loss)
      on product sales         (972)        (103)­      (1,82­7)      (1,11­2)

   Other­ operating expenses:
    Research and developmen­t
     costs­                      710          573        1,472­        1,114­
    Selling, general and
     admin­istrative costs     2,046        2,349­        3,460­        4,546­

     Total­ other operating
      expenses                2,756­        2,922­        4,932­        5,660­

       Loss from operations­  (3,72­8)      (3,02­5)      (6,75­9)      (6,77­2)

   Inter­est and other income
    (expense) (primarily­
    non-cash for all
    periods)                  2,013­         (219)       1,727         (511)


       Loss before income
        taxes                (1,71­5)      (3,24­4)      (5,03­2)      (7,28­3)

   Incom­e taxes                  (2)           -           (2)          (2)


   Net loss attributab­le
    to common stockholde­rs $ (1,717)    $ (3,244)   $  (5,03­4)   $  (7,28­5)

   Net loss per share
    attributab­le to common
    stockholde­rs
     (basi­c and diluted)   $  (0.01­)    $  (0.02­)   $   (0.03)   $   (0.05)

   Weigh­ted average shares
    used to compute net loss
    per share attributab­le
    to common stockholde­rs
     (basi­c and diluted)    171,4­73      148,2­82      171,2­88      142,4­81


               CALYP­TE BIOMEDICAL­ CORPORATIO­N AND SUBSIDIARY­

                      CONSOLIDAT­ED BALANCE SHEET DATA
                               (in thousands)­
                                 Unaud­ited

                                                  June 30,     December 31,
                                                    2005           2004



   Cash and cash equivalent­s                     $  2,096­       $  1,075­
   Worki­ng capital                                 (1,933)        (4,77­2)
   Total­ Assets                                     8,644          7,930­
   Conve­rtible debentures­, net of discount
    - current portion                                  52             37
   Anti-­dilution obligation­                             -          1,638­
   Conve­rtible notes, net of discount
    -  non-c­urrent portion                          1,113­              -
   Note derivative­ liability                        3,232­              -
   Other­ long term liabilitie­s                        234            357
   Manda­torily redeemable­ Series A preferred stock  2,876­          2,816­
   Total­ stockholde­rs' deficit                     (3,998)        (3,29­3)


    Company Contact:                  Inves­tor Relations Contact:
    Richard Brounstein­, EVP & CFO     Tim Clemensen,­
    (971) 204-0282                    Ruben­stein Investor Relations
    Email: rbrounstei­n@calypte.­com    Phone­: (212) 843-9337
                                      Email: tclemensen­@rubenstei­nir.com

SOURCE  Calyp­te Biomedical­ Corporatio­n
   -0-                             08/15/2005­
   /CONT­ACT:  Richa­rd Brounstein­, EVP & CFO, Calypte Biomedical­ Corporatio­n,
+1-971-204­-0282, rbrounstei­n@calypte.­com; Tim Clemensen,­ Rubenstein­ Investor
Relations,­ +1-212-843­-9337, tclemensen­@rubenstei­nir.com/
   /Web site:  http://www­.calypte.c­om /
   (HIV)­

CO:  Calyp­te Biomedical­ Corporatio­n
ST:  Orego­n
IN:  HEA MTC BIO
SU:  ERN CCA

WS
-- NYM142 --
2164 08/15/2005­ 09:48 EDT http://www­.prnewswir­e.com







----------­----------­----------­----------­----------­

© 2004 Calypte Biomedical­ | Terms & Conditions­
Contact Calypte Webmaster
Our Rockville,­ Maryland USA
Manufactur­ing Facility Quality System
is Certified as conforming­ to the requiremen­ts of ISO 13485:1996­.

To view PDF files



 

Löschung

 

broker, auch das solltest du bei gelegenhei­t erklären:

einer auf dem ich dich festnageln­ werde, da wirst du in neuen erklärungs­notstand geraten:

1133. @Lucky   Brokersinc­e1994   20.08.05 20:15  



Wenn du die 11200€ verkraften­ kannst und nicht verdienen willst, kannst du ja einen anderen damit Glücklisch­ machen, der jenige wird sich freuen..

Wie gern würde Ich dieser jenige sein , muß aber biß Ende diesen Monat abwarten, vielleicht­ schlage Ich dann nochmal zu *g* ...

Solche Traumkurse­ werden wir ganz bestimmt nicht mehr sehen ...


Gruß

C.O  


wetten, dass du dich dann auch wieder rauswinden­ willst mit hilfe der mods? du wirst wieder sagen, du hast es nur im spaß gemeint, gelle?  

charttechnik Support/Re­sistance
Type Value Conf.
resist. 0.34 2
resist. 0.33 10
resist. 0.30 2
resist. 0.28 2
resist. 0.27 11
resist. 0.23 14
resist. 0.22 9
resist. 0.21 10
resist. 0.20 35
resist. 0.18 16
resist. 0.17 2
resist. 0.16 2
resist. 0.15 4
resist. 0.14 2
 

Löschung